Akari Therapeutics Announces Phase 3 Trial Design

Biotech Investing

The company has announced the design of its Phase 3 pediatric trial in HSCT-TMA after an end-of-Phase 2 meeting with the FDA.

Akari Therapeutics (NASDAQ:AKTX) has announced the design of a Phase 3 trial in HSCT-TMA after a US Food and Drug Administration (FDA) end of Phase 2 meeting.

As quoted in the press release:

Akari also announces that, in another hematological condition, all six patients from the long-term Phase II PNH study who were transfusion dependent at entry are now transfusion independent on long-term treatment with nomacopan.

HSCT-TMA is an orphan hematological condition with no approved treatments and an estimated mortality rate of more than 80% in children with the severe form of the disease1. It is this severe form that is being targeted with nomacopan. Following a recent End-of-Phase II meeting with the FDA, Akari plans to initiate a single arm responder-based study design, based on treatment with nomacopan for up to 24 weeks. The primary endpoints are focused on disease response defined primarily by renal improvement and reduced transfusion dependence. The study will be in two parts, with data from seven patients in Part A used to confirm dosing and endpoints for Part B, with the pharmacokinetic (PK) modelling agreed with the FDA through Akari’s participation in the Model Informed Drug Discovery Program (MIDD). Following an interim efficacy and safety readout from Part A and meeting with the FDA, patients would then be recruited into Part B of the responder study.

While the role of complement inhibition is understood to play an important role in HSCT-TMA, LTB4 may also be an important target in reducing epithelial activation in both TMA and graft versus-host disease2 (GVHD) which often occur simultaneously. Daily dosing with nomacopan is also likely to be of a particular advantage in facilitating more complete complement suppression, especially in HSCT-TMA patients with high transfusion requirements.

Click here to read the full press release.

The Conversation (0)
×